An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial

Esmaily, Habibollah; Sahebkar, Amirhossein; Iranshahi, Mehrdad; Ganjali, Shiva; Mohammadi, Akram Miramin; Ferns, Gordon A.; Ghayour‐Mobarhan, Majid

doi:10.1007/s11655-015-2160-z

Cited by 161 publications

(112 citation statements)

References 45 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Gastrointestinal adverse events also seem to be present in the Sanmukhani et al () trial, where gastritis, nausea, and giddiness were also reported. Nausea was the only adverse event reported after administration of curcumin in the clinical trial of Yu et al (), and both Bergman et al () and Esmaily et al () reported no adverse events.…”

Section: Resultsmentioning

confidence: 97%

The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials

2015

View full text Add to dashboard Cite

Major depression is a common, recurrent, and chronic disease that negatively affects the quality of life and increases the risk of mortality. Several studies have demonstrated that curcumin, the yellow-pigmented substance of the turmeric, possesses antidepressant properties. The aim of this review is to meta-analytically assess the antidepressant effect of curcumin in patients with major depressive disorders. We extensively searched the literature until August 2015. The random-effect model was used to calculate the pooled standardized difference of means (SMD). Subgroup analyses were also performed to examine the effect of different study characteristics on the overall model. Six clinical trials met the inclusion criteria. Overall, curcumin administration showed a significantly higher reduction in depression symptoms [SMD = -0.34; 95% confidence interval (CI) = -0.56, -0.13; p = 0.002]. Subgroup analyses showed that curcumin had the highest effect when given to middle-aged patients (SMD = -0.36; 95% CI = -0.59; -0.13; p = 0.002), for longer duration of administration (SMD = -0.40; 95% CI = -0.64, -0.16; p = 0.001), and at higher doses (SMD = -0.36; 95% CI = -0.59, -0.13; p = 0.002). The administration of new formulation of curcumin (BCM-95) had non-significantly higher effect on depression as compared with the conventional curcumin-piperine formula. We conclude that there is supporting evidence that curcumin administration reduces depressive symptoms in patients with major depression.

show abstract

Section: Resultsmentioning

confidence: 97%

The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials

2015

View full text Add to dashboard Cite

show abstract

“…It is a nutraceutical with documented safety and numerous pharmacological effects such as antioxidant, antimicrobial, anti-fungal, anti-inflammatory, anti-angiogenic and pro-apoptotic properties [7,8]. Several lines of evidence have indicated the efficacy of curcumin supplementation against several human diseases such as anxiety and depression [9,10], osteoarthritis [11,12], metabolic syndrome [13], dyslipidemia [14][15][16], nonAbstract ▼ Background: Curcumin, the bioactive ingredient of turmeric, has been shown to improve the treatment of peptic ulcer (PU) in animal studies. However, clinical studies confirming this effect of curcumin have been scant.…”

Section: Introductionmentioning

confidence: 99%

Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial

et al. 2016

View full text Add to dashboard Cite

show abstract

“…By contrast, in a randomized, double-blind, crossover trial in 30 obese patients with mild depressive symptoms (mean ± baseline BDI = 9.89 ± 6.50), curcumin significantly reduced anxiety symptoms but had no effect on depressive symptoms or body weight [123].…”

Section: Pharmacotherapy Studies Of Comorbid Depression and Obesitymentioning

confidence: 77%

Managing comorbid obesity and depression through clinical pharmacotherapies

McElroy

Guerdjikova

Mori

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

When treating a patient with a mood disorder and obesity, both conditions need to be a focus of clinical attention. Psychotropic medications that have minimal weight gain effects should be used if possible. Weight-loss agents can probably be used in some mood disorder patients, but must be done so cautiously and with a full understanding of their potential psychiatric effects and interactions with psychotropic medications. Knowledge of the pharmacotherapy of binge eating and psychotropic-induced weight gain is also crucial.

show abstract

An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial

Abstract: Curcumin has a potential anti-anxiety effect in individuals with obesity.

Cited by 161 publications

References 45 publications

The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials

The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials

Adjunctive Therapy with Curcumin for Peptic Ulcer: a Randomized Controlled Trial

Managing comorbid obesity and depression through clinical pharmacotherapies

Contact Info

Product

Resources

About